Clinical trialNo phase (not a drug trial)Recruiting
Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals
A Prospective Cohort to Evaluate the Ability of Different Body fLuid-derived Approaches to Detect EArly-stage Cancers Among High-risk Individuals
- Outcome
- Ongoing
- Phase
- No phase (not a drug trial)
- Status
- Recruiting
- Study type
- Interventional
- Start
- 16 March 2026
- Expected end
- June 2030
- Enrollment
- 5,909 participants
- Sites
- 1
- Primary outcomes
- sensitivity of techniques derived from body fluids in the detection of any invasive cancer
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 30 March 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
LEAH is a prospective, observational, single-centre, non-randomised, open-label study of people at increased risk of cancer or malignant disease. The main objective of LEAH is to evaluate and compare the sensitivity of different tests on body fluids to detect cancers that will occur within 3 years of inclusion in the study, in a cohort of individuals identified as being at increased risk of cancer.